Hepatitis B vaccine is not the same as hepatitis B immune globulin. Hepatitis B vaccine is generally used after human injection, and through about three injections, the body is prompted to produce an immune response and further develop an immune protection mechanism. After the patient forms hepatitis B surface antibody, if the titer is more than 10mIU/mL or more, he is immune to chronic viral hepatitis B and will not be infected with chronic viral hepatitis B. For hepatitis B immunoglobulin, its main role is for normal people, especially medical workers in the middle of surgery or after contact with the blood of hepatitis B patients due to open wounds. In this case, the patient needs to be injected with hepatitis B immunoglobulin, which will greatly reduce the possibility of the patient contracting chronic viral hepatitis B through the blood. Hepatitis B immunoglobulin injections are an active preventive treatment, and their effect is generally different from that of the hepatitis B vaccine. The hepatitis B vaccination is designed to promote the production of antibodies to further protect the body from hepatitis B virus infection. Hepatitis B immunoglobulin is an active prophylaxis for patients with high-risk conditions, such as lacerations during surgery or after exposure to blood from open wounds.